CA2692776A1 - Sel de chlorure d'hydrogene d'un compose 5-oxazol-2-yl-quinoline substitue et leur procede de production - Google Patents

Sel de chlorure d'hydrogene d'un compose 5-oxazol-2-yl-quinoline substitue et leur procede de production Download PDF

Info

Publication number
CA2692776A1
CA2692776A1 CA 2692776 CA2692776A CA2692776A1 CA 2692776 A1 CA2692776 A1 CA 2692776A1 CA 2692776 CA2692776 CA 2692776 CA 2692776 A CA2692776 A CA 2692776A CA 2692776 A1 CA2692776 A1 CA 2692776A1
Authority
CA
Canada
Prior art keywords
compound
formula
crystalline form
mixture
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692776
Other languages
English (en)
Inventor
Man Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692776A1 publication Critical patent/CA2692776A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA 2692776 2007-07-10 2008-07-03 Sel de chlorure d'hydrogene d'un compose 5-oxazol-2-yl-quinoline substitue et leur procede de production Abandoned CA2692776A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95947907P 2007-07-10 2007-07-10
US60/959,479 2007-07-10
PCT/US2008/008260 WO2009009002A2 (fr) 2007-07-10 2008-07-03 Sel de chlorure d'hydrogène d'un composé 5-oxazol-2-yl-quinoline substitué et leur procédé de production

Publications (1)

Publication Number Publication Date
CA2692776A1 true CA2692776A1 (fr) 2009-01-15

Family

ID=40229337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692776 Abandoned CA2692776A1 (fr) 2007-07-10 2008-07-03 Sel de chlorure d'hydrogene d'un compose 5-oxazol-2-yl-quinoline substitue et leur procede de production

Country Status (5)

Country Link
US (1) US20110003780A1 (fr)
EP (1) EP2176257A2 (fr)
JP (1) JP2010533175A (fr)
CA (1) CA2692776A1 (fr)
WO (1) WO2009009002A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565599C (fr) * 2004-05-18 2012-07-31 Schering Corporation 2-quinolyle-oxazoles substitues utiles comme inhibiteurs du pde4
WO2006105401A2 (fr) * 2005-03-30 2006-10-05 Schering Corporation Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee
CA2657902A1 (fr) * 2006-07-11 2008-01-17 Schering Corporation Sel de xinafoate d'un compose de 5-oxazol-2-yl-quinoline substitue

Also Published As

Publication number Publication date
US20110003780A1 (en) 2011-01-06
JP2010533175A (ja) 2010-10-21
EP2176257A2 (fr) 2010-04-21
WO2009009002A2 (fr) 2009-01-15
WO2009009002A3 (fr) 2009-05-07

Similar Documents

Publication Publication Date Title
US20220281815A1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
AU2015371294B2 (en) Compounds, compositions, and methods for increasing CFTR activity
CA2993450C (fr) Composes, compositions et procedes pour augmenter l'activite du cftr
CN104892582B (zh) 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
EP2928879B1 (fr) Dérivés de phenylethylpyridine comme inhibiteurs de pde4 et en tant qu'antagonistes des récepteurs muscariniques
EP2928880B1 (fr) Dérivés de phenylethylpyridine comme inhibiteurs de pde4 et en tant qu'antagonistes des récepteurs muscariniques
EP2196465A1 (fr) Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
EP3077385B1 (fr) Dérivés de hétéroaryle pour le traitement de maladies respiratoires
JP2013517283A (ja) 電位依存性ナトリウムチャネル遮断薬
JP2023500263A (ja) アドレナリン受容体ａｄｒａｃ２の阻害剤
AU2007273007B2 (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
TW201625600A (zh) 胺基酯衍生物
CA2692776A1 (fr) Sel de chlorure d'hydrogene d'un compose 5-oxazol-2-yl-quinoline substitue et leur procede de production
EP3152203A1 (fr) Dérivés de 3,5-dichloro,4-(3,4-(cyclo-)alcoxyphényl)-2-carbonyloxy)éthyl)pyridine utilisés comme inhibiteurs de pde-4
CA2692781A1 (fr) Procede de production de 5-quinolyl-oxazoles substitues et sels pharmaceutiquement acceptables de ceux-ci

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140703